By admin 
CureSearch for Children’s Cancer, a leading national non-profit foundation dedicated to accelerating the development of new, less toxic treatments for pediatric malignancies, has formally announced the appointment of Mark Zafra to its Board of Directors. Zafra, a highly accomplished executive currently serving as the Chief Procurement Officer at LiveRamp, brings over 20 years of expertise in global strategic sourcing, supply chain management, and organizational transformation to the foundation. His appointment comes at a critical juncture for the organization as it seeks to scale its impact and bridge the funding gap between laboratory discovery and clinical application in the field of pediatric oncology.
The addition of Zafra to the governing body is viewed by industry analysts and organizational leadership as a strategic move to integrate high-level corporate efficiency with the foundation’s mission-driven initiatives. Beyond his professional accolades, Zafra’s relationship with the cause is deeply personal; as a cancer survivor marking two decades since his initial diagnosis, he offers a unique dual perspective that encompasses both the rigors of corporate governance and the lived experience of a patient navigating a life-threatening illness.
A Career Defined by Strategic Leadership and Operational Excellence
Mark Zafra’s professional trajectory is marked by a series of leadership roles within some of the world’s most influential technology and healthcare corporations. At LiveRamp, a prominent data connectivity platform, he oversees a complex portfolio that includes global strategic sourcing, purchasing, corporate travel, and accounts payable. His role is central to the company’s operational stability and financial health, requiring a meticulous approach to vendor management and resource allocation.
Prior to his tenure at LiveRamp, Zafra held senior leadership positions at Twitter, where he was instrumental in scaling procurement operations during periods of rapid international expansion. His resume also includes significant contributions to Allianz Fireman’s Fund, HP, and Agilent Technologies. Notably, his experience at McKesson—one of the largest healthcare services and medical supply companies in North America—provides him with a foundational understanding of the healthcare supply chain, a perspective that is directly applicable to the logistical and financial challenges inherent in clinical research and drug development.
Throughout his career, Zafra has been recognized for his ability to lead large-scale transformation initiatives. These efforts often involve streamlining complex processes to drive innovation and maximize efficiency. For a non-profit organization like CureSearch, which relies on the strategic allocation of donor funds to high-potential research projects, Zafra’s ability to optimize operational workflows is expected to enhance the foundation’s capacity to deliver results.
The State of Childhood Cancer Research: A Contextual Analysis
The appointment of a procurement and supply chain expert to a medical research board highlights an evolving trend in the non-profit sector: the need for "venture philanthropy" models that treat research funding with the same rigor as corporate investments. Pediatric cancer remains the leading cause of death by disease among children in the United States. According to data from the National Cancer Institute (NCI) and the American Cancer Society, approximately 10,000 children under the age of 15 are diagnosed with cancer annually in the U.S. alone.
While the overall five-year survival rate for childhood cancer has risen to approximately 85%, these statistics mask a grimmer reality for specific high-risk subtypes. Furthermore, the treatments currently available—often developed decades ago for adult populations—frequently result in severe, lifelong side effects, including secondary cancers, heart disease, and cognitive impairments.
CureSearch for Children’s Cancer addresses a specific failure in the pharmaceutical market known as the "Valley of Death." Because pediatric cancers are relatively rare compared to adult cancers, major pharmaceutical companies often find little financial incentive to invest the hundreds of millions of dollars required to move a pediatric drug through the clinical trial process. CureSearch fills this void by funding Phase I and Phase II clinical trials, providing the necessary data to de-risk these projects and encourage further investment from larger industry players.
Personal Resilience and the Twenty-Year Milestone
Mark Zafra’s commitment to CureSearch is underscored by his personal history as a cancer survivor. This year marks the 20th anniversary of his first diagnosis, a milestone that serves as both a personal triumph and a catalyst for his advocacy work. In the realm of non-profit governance, survivors on the board often serve as the "moral compass" of the organization, ensuring that the patient’s needs remain the central focus of all strategic decisions.
To commemorate his 20-year survival milestone, Zafra is participating in the CureSearch Ultimate Hike in Jackson, Wyoming. The Ultimate Hike is the organization’s signature endurance fundraising event, challenging participants to complete a 28.3-mile trek in a single day. This event is not merely a physical challenge; it is a symbolic representation of the arduous journey faced by children undergoing cancer treatment. Funds raised through the hike are directed toward cutting-edge research and the acceleration of clinical trials.
Zafra’s participation in the hike, coupled with his board service, demonstrates a holistic commitment to the organization. "It is with great enthusiasm and a deep sense of responsibility that I join CureSearch’s Board of Directors," Zafra stated. "As a survivor myself, I am a passionate advocate for advancing cancer research and am honored by the opportunity to contribute my skills and experience to a mission that matters deeply to me."
Official Responses and Organizational Vision
The leadership at CureSearch has expressed significant optimism regarding Zafra’s appointment. Jared Brancazio, the CureSearch Board Chair, highlighted the intersection of Zafra’s professional background and personal dedication as a primary asset for the foundation’s future.
"Mark’s professional leadership and personal commitment to advancing cancer research make him an incredible addition to the CureSearch Board," Brancazio said. "We’re honored to have him help guide our work and accelerate our impact."
The board’s enthusiasm reflects a broader strategy to diversify the expertise within its leadership. By including executives with backgrounds in procurement and supply chain, CureSearch is positioned to better navigate the complexities of the global research landscape. This includes managing relationships with academic institutions, biotechnology firms, and regulatory bodies. The goal is to ensure that every dollar raised is utilized with maximum efficacy, reducing overhead and speeding up the timeline for bringing new therapies to the bedside.
Chronology of Organizational Growth and Future Outlook
CureSearch has a long history of pivoting its strategy to meet the most urgent needs of the pediatric oncology community. Originally functioning as a traditional grant-making body, the organization has shifted its focus over the last decade toward a more targeted, results-oriented approach.
- 1980s-1990s: The organization’s predecessors focused largely on supporting the Children’s Oncology Group (COG) and broad academic research.
- 2010s: Recognizing the "Valley of Death" in drug development, CureSearch began prioritizing projects with a clear path to clinical trials and commercialization.
- 2020-Present: The foundation has intensified its focus on "Catapult Awards" and "Acceleration Funds," which provide the critical capital needed to move therapies out of the lab.
- 2024: The appointment of Mark Zafra signals a move toward strengthening the operational and strategic infrastructure of the board to support multi-million dollar research portfolios.
Looking forward, the implications of Zafra’s appointment are expected to be felt in the foundation’s strategic sourcing of research partners. As Chief Procurement Officer, Zafra is an expert in identifying value and ensuring accountability—traits that are essential when the "product" being developed is a life-saving medical treatment.
Broader Impact on Pediatric Oncology Advocacy
The integration of high-level corporate executives into the fight against childhood cancer has broader implications for the sector. It signals to the philanthropic community that pediatric cancer research is not just a charitable cause, but a field requiring sophisticated management and strategic oversight.
Zafra’s role will likely involve advising on the financial sustainability of research initiatives and helping the foundation navigate the economic complexities of the healthcare industry. His presence on the board may also encourage other corporate leaders to engage with the cause, potentially opening new avenues for corporate social responsibility (CSR) partnerships and large-scale corporate giving.
As CureSearch continues to fund innovative research—such as immunotherapy, targeted molecular therapies, and genomic sequencing—the oversight provided by a diverse board of directors will be paramount. The ultimate goal remains clear: ensuring that the 43 children diagnosed with cancer every day in the United States have access to treatments that not only save their lives but allow them to thrive long after their diagnosis.
Through the combination of Mark Zafra’s professional acumen and his personal journey of resilience, CureSearch for Children’s Cancer reaffirms its commitment to transforming the landscape of pediatric oncology. His appointment is a testament to the power of combining professional expertise with a deeply rooted personal mission to solve one of the most challenging problems in modern medicine.
